Access Statistics for Margaret K. Kyle

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 1 16 1 1 2 29
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 0 0 0 0 0 3
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 0 0 0 0 0 19
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 0 0 0 0 0 13
Assessing the population health impact of market interventions to improve access to antiretroviral treatment 0 0 0 0 0 0 0 8
COVID-19 and clinical trials 0 0 0 0 0 0 0 4
Competition Law, Intellectual Property, and the Pharmaceutical Sector 0 0 0 0 1 1 3 32
Competition and the Efficiency of Markets for Technology 0 0 0 0 0 0 2 3
Competition and the Efficiency of Markets for Technology 0 0 0 94 0 0 1 135
Competition and the Efficiency of Markets for Technology 0 0 0 70 0 0 1 129
Competition and the Efficiency of Markets for Technology 0 0 0 0 0 0 2 4
Competition law, intellectual property, and the pharmaceutical sector 0 0 0 0 1 1 5 39
Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did They Get Easier During the Banking Boom? Did It Matter to Bank Lending? 0 0 0 189 0 0 2 819
Did U.S. bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending? 0 0 0 138 0 0 0 532
Do Patents Work? Evidence from Pharmaceutical Innovation 0 0 0 0 1 1 1 16
Economic Issues in Assessing Potential and Nascent Competition 0 0 0 0 1 1 5 12
Estimating the Benefits of Cancer Treatments 0 0 0 0 0 0 1 9
Estimating the Benefits of Innovation 0 0 0 0 0 0 1 44
Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration 0 0 0 0 0 0 2 36
Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act 0 0 0 4 0 1 2 49
Government Free-riding in Research Funding 0 0 0 0 0 0 0 8
Hot tub time machine? What role for Towercast in EU merger control 0 0 0 0 0 1 1 1
Incentives for pharmaceutical innovation: What’s working, what’s lacking 0 0 0 1 0 0 0 7
Inefficiencies in technology transfer: theory and empirics 0 0 0 0 0 0 2 2
Inefficiencies in technology transfer: theory and empirics 0 0 0 13 0 0 2 97
Inefficiencies in technology transfer: theory and empirics 0 0 0 58 0 0 1 326
Inefficiencies in the sale of ideas: theory and empirics 0 0 0 106 0 0 2 118
Inefficiencies in the sale of ideas: theory and empirics 0 0 0 0 0 0 1 1
Innovation pharmaceutique: comment combler le retard français ? 0 0 0 1 0 0 0 15
Intellectual Property Rights and Access to Innovation: Evidence from TRIPS 0 1 5 61 2 4 16 198
Intellectual Property Rights and Access to Innovation: Evidence from TRIPS 0 0 0 0 0 0 0 7
Intellectual property rights and access to innovation: evidence from TRIPS 0 0 0 0 1 2 4 37
Intersection of Intellectual Property and Competition Policy in Recent Cases 0 0 0 0 0 0 2 7
Investments in Pharmaceuticals Before and After TRIPS 0 1 2 41 0 3 5 157
Investments in Pharmaceuticals Before and After TRIPS 0 0 0 88 0 0 3 261
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs 0 0 0 0 0 0 3 53
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs 0 0 0 0 0 2 2 16
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs 0 0 0 45 0 2 2 59
Korean pharmaceutical industry policy: lessons for Korea 0 0 0 0 0 1 1 6
Productivity and competitiveness in the euro area: A view from France 0 0 0 0 0 2 6 72
Productivity and competitiveness in the euro area: A view from France 0 0 0 0 0 0 4 11
Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research 0 0 1 125 0 0 3 365
Strategic Interaction Among Governments in the Provision of a Global Public Good 0 0 0 30 0 0 1 68
Strategic Responses to Parallel Trade 0 0 0 131 0 0 1 392
Strategic interaction among governments in the provision of a global public good 0 0 0 0 0 1 2 18
Strategic interaction among governments in the provision of a global public good 0 0 0 0 0 0 1 10
Study for European Commission (DG Internal Market, Industry, Entrepreneurship and SMEs) on supplementary patent certificates 0 0 0 0 1 1 2 128
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals 0 0 0 0 0 0 1 3
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals 0 0 0 0 0 0 0 1
The Effects of Pharmaceutical Innovation on Cancer Mortality 0 0 0 10 0 1 2 45
The Effects of Pharmaceutical Innovation on Cancer Mortality Rates 0 0 2 98 0 2 7 201
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect 0 0 0 0 0 0 2 59
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect 0 0 0 23 0 0 5 89
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect* 0 0 0 0 0 0 3 5
The Single Market in Pharmaceuticals 0 0 0 0 0 0 0 13
The economics of new product launches and access to pharmaceutical products in the EU: A perspective on the EC’s proposed reform of the EU pharmaceutical legislation 0 0 0 3 0 0 0 10
Total Working Papers 0 2 11 1,345 9 28 117 4,801


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 1 2 30 0 2 9 88
Competition and the Efficiency of Markets for Technology 0 0 0 21 0 0 2 85
Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales 0 0 2 29 0 1 6 136
Does locale affect R&D productivity? the case of pharmaceuticals 0 0 1 26 0 1 4 97
Generic competition and market exclusivity periods in pharmaceuticals 2 2 13 179 5 15 45 473
Incentives for pharmaceutical innovation: What’s working, what’s lacking 0 0 3 12 2 3 12 39
Intellectual Property Protection and the Geography of Trade 0 0 0 40 1 3 5 211
Investments in Pharmaceuticals Before and After TRIPS 1 2 10 187 4 10 29 572
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs 0 0 0 12 1 2 3 131
Lessons for the United States from Pharmaceutical Regulation Abroad 1 1 1 1 2 2 2 2
Objective and self‐report work performance measures: a comparative analysis 0 0 0 1 0 0 1 3
Pharmaceutical Price Controls and Entry Strategies 2 2 7 533 7 7 23 1,209
Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research 0 0 0 15 0 3 5 100
Strategic Responses to Parallel Trade 0 0 1 96 0 0 3 353
Strategic interaction among governments in the provision of a global public good 0 0 1 14 0 0 2 80
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals 0 0 0 10 1 2 4 55
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect 0 0 0 23 1 3 8 208
The Single Market in Pharmaceuticals 0 0 2 21 0 0 4 88
The role of firm characteristics in pharmaceutical product launches 0 0 0 21 0 0 1 82
Total Journal Articles 6 8 43 1,271 24 54 168 4,012


Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Did US Bank Supervisors Get Tougher during the Credit Crunch? Did They Get Easier during the Banking Boom? Did It Matter to Bank Lending? 0 1 1 45 1 2 6 171
Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions 0 1 2 76 1 3 11 223
Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity 0 3 11 111 5 14 37 395
Public and Private Spillovers: Location and the Productivity of Pharmaceutical Research 0 0 0 0 0 0 0 91
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals 0 0 0 19 0 1 1 60
The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches 0 0 1 105 1 1 5 325
Total Chapters 0 5 15 356 8 21 60 1,265


Software Item File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
MATLAB/C code for GIG and BNLG common value auction specifications 1 2 3 1,673 1 2 12 5,710
Total Software Items 1 2 3 1,673 1 2 12 5,710


Statistics updated 2025-06-06